We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




New Diagnostic Approach Combines DNA Testing With AI Analysis for Coronary Heart Disease Risk Assessment

By LabMedica International staff writers
Posted on 10 May 2023

Although preventative health is crucial in managing cardiovascular disease, for the last three decades, healthcare professionals have had to depend on limited, one-dimensional methods to guide preventive care. More...

Currently, primary care practitioners have only the Framingham Risk Score (FRS) and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator to predict the likelihood of future heart disease. However, these tools demonstrate poor performance in both research environments and real-world practice. A novel test now merges epigenetics, genetics, high-throughput computing, and artificial intelligence to pinpoint individuals at risk for coronary heart disease, a critical factor in delivering cost-effective health care to adults.

Cardio Diagnostics Inc. (Chicago IL, USA) has developed Epi+Gen CHD as an alternative to the existing tests available. Epi+Gen CHD not only identifies those at a lower risk of developing coronary heart disease, which current tests accurately do, but also recognizes those at a higher risk, an aspect where current tests fall short. The test focuses on coronary heart disease risk since it is the most prevalent type of heart disease and the primary cause of heart attacks.

Epi+Gen CHD adopts an entirely new approach to evaluating coronary heart disease risk by integrating DNA testing of genetic and epigenetic biomarkers with AI-driven analysis to produce personalized risk profiles for each patient. The test assesses DNA methylation status at three loci and genotype at five loci. An AI-guided algorithm then interprets the DNA methylation results in relation to genetic variations. This method enables the understanding of epigenetic signatures that might otherwise be obscured by background genetic variation. As the first comprehensive and sensitive genetic-epigenetic clinical test for determining the three-year heart attack risk, Epi+Gen CHD represents the future of preventive cardiovascular disease care.

Related Links:
Cardio Diagnostics Inc. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.